GNLX Genelux Corp

Price (delayed)

$2.89

Market cap

$129.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$122.81M

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product ...

Highlights
GNLX's gross profit has surged by 100% year-on-year
Genelux's revenue has surged by 100% YoY
GNLX's equity has soared by 99% from the previous quarter but it is down by 23% YoY
Genelux's quick ratio has soared by 54% from the previous quarter but it has decreased by 21% YoY
GNLX's debt is up by 48% since the previous quarter and by 40% year-on-year
The net income has contracted by 14% YoY and by 4.5% from the previous quarter

Key stats

What are the main financial stats of GNLX

GNLX stock price

How has the Genelux stock price performed over time
Intraday
-2.36%
1 week
0.7%
1 month
1.4%
1 year
-16.71%
YTD
-33.72%
QTD
-3.99%

Financial performance

How have Genelux's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$34.58M
Net income
-$33.58M
Gross margin
N/A
Net margin
N/A
GNLX's gross profit has surged by 100% year-on-year
Genelux's revenue has surged by 100% YoY
The net income has contracted by 14% YoY and by 4.5% from the previous quarter
The company's operating income fell by 10% YoY and by 4.1% QoQ

Price vs fundamentals

How does GNLX's price correlate with its fundamentals

Growth

What is Genelux's growth rate over time

Valuation

What is Genelux stock price valuation
P/E
N/A
P/B
5.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 3.4% YoY
GNLX's equity has soared by 99% from the previous quarter but it is down by 23% YoY
GNLX's price to book (P/B) is 29% lower than its last 4 quarters average of 8.0
Genelux's revenue has surged by 100% YoY

Efficiency

How efficient is Genelux business performance
GNLX's ROE has plunged by 88% YoY and by 14% from the previous quarter
Genelux's return on invested capital has shrunk by 80% YoY and by 2.1% QoQ
Genelux's return on assets has shrunk by 67% YoY and by 11% QoQ

Dividends

What is GNLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GNLX.

Financial health

How did Genelux financials performed over time
Genelux's total assets has surged by 70% QoQ but it has decreased by 17% YoY
Genelux's quick ratio has soared by 54% from the previous quarter but it has decreased by 21% YoY
GNLX's debt is 89% smaller than its equity
GNLX's equity has soared by 99% from the previous quarter but it is down by 23% YoY
GNLX's debt to equity has soared by 83% YoY but it is down by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.